ИСТИНА |
Войти в систему Регистрация |
|
ИСТИНА ИНХС РАН |
||
Until about the beginning of the 2000, the main innovative direction in pharmacy (so called Drug Discovery) was the creation of new active substances – molecules. This process is to search and multiple trials of newly synthesized or chemically modified natural organic compounds. And on statistical tick of about 10,000 "starting" connections to industrial production comes only one molecule. Drug trials can last for many years , with an average of 9-12 years , and the cost of development , according to various estimates , may be from 0.3 to 2 (average 0.8 ) billion US $ [1]. Another area of innovation is to improve the pharmacological properties and safety already in use in the pharmaceutical active substances due to their directed transport in a given region of the organism a given region of the body, organ or cells , as well as speed control , time and place of action of a drug in the body (so called Drug Delivery Systems). Here, the duration of the development and the cost is usually several times shorter and cheaper. However, and this way allows you to output in high-performance treatment medications.According to the above reasons, the share of economic development Drug Delivery Systems has recently become dominant. So worldwide sales of drugs in 2012 , made by technology Drug Delivery, estimated at ~ > 140 billion US $, while the market of Drug Discovery is about ~ > 40-56 billion US $. This is an important topical issue gets , respectively, and avalanche increase in the number of publications on the topic "nanotechnology and creation of DDS ." It should be noted that the accelerated development of Drug Delivery developments particularly advantageous for countries with insufficient manufacturing their own drugs , but seeking to accelerate the development in this area. Combination of materials set forth in this paper favors the development of alternative ways of creating new drugs by modifying the existing and substances used in practice.